Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) - Pipeline Review, H1 2018

  • ID: 4540575
  • Report
  • 67 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • 4SC AG
  • AlfaSigma SpA
  • HitGen LTD
  • MEI Pharma Inc
  • Mirati Therapeutics Inc
  • MORE
Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) - Pipeline Review, H1 2018

Summary:

Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) pipeline Target constitutes close to 7 molecules. Out of which approximately 5 molecules are developed by companies and remaining by the universities/institutes. The latest report Histone Deacetylase 4 - Pipeline Review, H1 2018, outlays comprehensive information on the Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) - Histone deacetylase 4 (HDAC4) is a protein encoded by the HDAC4 gene. It is responsible for the deacetylation of lysine residues on the N-terminal part of the core histones. It plays an important role in transcriptional regulation, cell cycle progression and developmental events. It acts via the formation of large multiprotein complexes. The molecules developed by companies in Phase III, Phase II and Preclinical stages are 1, 2 and 2 respectively.

Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Oncology, Cardiovascular and Ophthalmology which include indications Non-Small Cell Lung Cancer, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Bile Duct Cancer (Cholangiocarcinoma), Bladder Cancer, Breast Cancer, Colon Cancer, Congestive Heart Failure (Heart Failure), Cutaneous T-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, Essential Thrombocythemia, Follicular Lymphoma, Gallbladder Cancer, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Leiomyosarcoma, Liver Cancer, Lung Cancer, Metastatic Transitional (Urothelial) Tract Cancer, Mycosis Fungoides, Myelodysplastic Syndrome, Pancreatic Cancer, Post-Polycythemia Vera Myelofibrosis (PPV-MF), Prostate Cancer, Retinitis Pigmentosa (Retinitis) and Sezary Syndrome.

Furthermore, this report also reviews key players involved in Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The report provides a snapshot of the global therapeutic landscape for Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98)
  • The report reviews Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) targeted therapeutics
Reasons for Purchase:
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • 4SC AG
  • AlfaSigma SpA
  • HitGen LTD
  • MEI Pharma Inc
  • Mirati Therapeutics Inc
  • MORE
Introduction

Report Coverage

Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) - Overview

Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) - Companies Involved in Therapeutics Development

4SC AG

AlfaSigma SpA

HitGen LTD

MEI Pharma Inc

Mirati Therapeutics Inc

Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) - Drug Profiles

Gene Therapy to Activate HDAC4 for Heart Failure - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy to Activate HDAC4 for Retinitis Pigmentosa - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HG-3001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

mocetinostat - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pracinostat - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

resminostat - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ST-3595 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) - Dormant Products

Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) - Discontinued Products

Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) - Product Development Milestones

Featured News & Press Releases

Jan 31, 2018: Positive DSMB safety review of 4SC's pivotal RESMAIN study of resminostat in CTCL

Jan 11, 2018: Helsinn Group and MEI Pharma Announce that Pracinostat has Received Orphan Drug Designation from the European Medicines Agency for the Treatment of acute myeloid leukemia (AML)

Dec 20, 2017: 4SC receives Pediatric Investigation Plan Waiver for resminostat in CTCL from the European Medicines Agency

Dec 13, 2017: 4SC receives milestone payment from Immunic

Oct 12, 2017: Mirati Therapeutics' Mocetinostat Included In Stand Up To Cancer's Cutting-Edge Clinical Trial Initiative for NSCLC Patients

Oct 10, 2017: Resminostat demonstrates potential to significantly alleviate itching in CTCL patients

Sep 13, 2017: Phase I study of 4SC's resminostat indicates efficacy in biliary tract cancer

Aug 02, 2017: Helsinn Group and MEI Pharma Announce First Patient Dosed in Pivotal Phase 3 Study of Pracinostat and Azacitidine in Acute Myeloid Leukemia

Jun 14, 2017: Helsinn Group and MEI Pharma Announce First Patient Dosed in Phase 2 Dose-Optimization Study of Pracinostat and Azacitidine in Myelodysplastic Syndrome

Jun 05, 2017: Helsinn Group and MEI Pharma Report Correlation between Mutations in DNA Methylation Pathway and Clinical Response in Phase II Study of Pracinostat and Azacitidine in Acute Myeloid Leukemia

May 18, 2017: Helsinn Group and MEI Pharma Announce Upcoming Presentations of Gene Mutation and Clinical Response Data from Phase II Study of Pracinostat and Azacitidine in Acute Myeloid Leukemia

Jan 24, 2017: Overall survival benefit for resminostat in first-line liver cancer study subgroup

Jan 05, 2017: Mirati Therapeutics Provides Update On Mocetinostat Program

Dec 16, 2016: First patient enrolled in pivotal RESMAIN study of resminostat in CTCL

Dec 05, 2016: Helsinn Group and MEI Pharma Report Prolongation of Survival Results from Phase 2 Clinical Study of Pracinostat and Azacitidine in Acute Myeloid Leukemia

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Therapy Areas, H1 2018

Number of Products under Development by Indications, H1 2018

Number of Products under Development by Indications, H1 2018 (Contd..1), H1 2018

Number of Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Number of Products under Investigation by Universities/Institutes, H1 2018

Products under Investigation by Universities/Institutes, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Pipeline by 4SC AG, H1 2018

Pipeline by AlfaSigma SpA, H1 2018

Pipeline by HitGen LTD, H1 2018

Pipeline by MEI Pharma Inc, H1 2018

Pipeline by Mirati Therapeutics Inc, H1 2018

Dormant Products, H1 2018

Dormant Products, H1 2018 (Contd..1), H1 2018

Discontinued Products, H1 2018

List of Figures

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Therapy Areas, H1 2018

Number of Products under Development by Top 10 Indications, H1 2018

Number of Products by Mechanism of Actions, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • 4SC AG
  • AlfaSigma SpA
  • HitGen LTD
  • MEI Pharma Inc
  • Mirati Therapeutics Inc
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll